According to the research report titled ‘Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market 2021-2028’, available with MarketStudyReport, global non-alcoholic steatohepatitis (NASH) biomarker market is expected to register a compound annual growth rate of 21.28% over the forecast timeframe 2021-2028.
 

As per the report findings, worldwide non-alcoholic steatohepatitis (NASH) biomarker market growth is mainly driven by rising prevalence of NASH disease coupled with increasing incidence of metabolic comorbidities. In addition, growing awareness about non-alcoholic fatty liver disease (NAFLD) is likely to enhance the industry outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3584756/
 

On the contrary, dearth of specialized diagnostic tests for NAFLD, as well as adverse effects associated with NASH therapies may impede market expansion in the forthcoming years.
 

Based on type, the market is split into serum biomarker, apoptosis biomarker, hepatic fibrosis biomarker, oxidative stress biomarker, and others. In terms of industry, the market is split into pharma & CRO industry, academic research key, diagnostic lab, and hospital.
 

From a regional perspective, the market segmentation covers North America (U.S., Canada), Europe (UK, Germany, Spain, France, Russia, Italy, Rest of Europe), MEA (South Africa, Turkey, Saudi Arabia, UAE), Asia Pacific (Japan, China, South Korea, India, Australia, New Zealand, Rest of APAC), and Latin America (Mexico and Brazil).
 

Among the above-mentioned regions, Asia-Pacific market is expected to grow rapidly over the forecast period, owing to technological advancements in healthcare infrastructure, surge in prevalence of NASH, and improving economic conditions in the region. Moreover, rising healthcare awareness in emerging nations like China & India is anticipated to have a positive impact on regional market growth in the coming years.
 

Considering the competitive landscape, major companies influencing global non-alcoholic steatohepatitis (NASH) biomarker  industry trends are Allergan plc, Merck & Co. Inc., Novartis International AG, Viking Therapeutics Inc., Bristol Myers Squibb Co., Novo Nordisk  A/S, Genfit SA, Pfizer Inc., Madrigal Pharmaceuticals Inc., Gilead Sciences Inc., AstraZeneca plc, Zydus Cadila (Cadila Healthcare Ltd.), and Siemens Healthineers AG.